FLFangzhou Li

Fangzhou Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fangzhou Li has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Xing-Jie Liang

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, PR China

    19 shared publications
  • Mingmei Li

    State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China

    4 shared publications
  • Pengli Gao

    State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China

    4 shared publications
  • Bozhang Xia

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing 100190 P. R. China

    3 shared publications
  • Chenlu Huang

    State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, People’s Republic of China

    3 shared publications
  • Dunwan Zhu

    State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China

    3 shared publications

Latest Publications

  • Open Access

    Pulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery

    by Weilun Sun, Ti-Qiang Zhou, Yuanyu Huang, Xing-Jie Liang, Fangzhou Li


  • Boosting long-term immunity with bioengineered nanovaccines

    by Mingmei Li, Weilun Sun, Xiang Zheng, Pengli Gao, Linhua Zhang, Dunwan Zhu, Fangzhou Li

  • Open Access

    From Uptake to Therapeutic Function in Engineered Exosome Delivery Systems

    by Yiwei Li, Limin Jin, Pengli Gao, Mingmei Li, Zengkai Zhao, Jianjun Jiang, Ming An, Fangzhou Li

    Engineered exosomes are increasingly recognized as promising vehicles for precision drug delivery. Genetic display, chemical modification, physical loading, and hybrid vesicle construction have expanded their applications, while introducing additional variables to the interpretation of delivery outcomes. Because engineering can alter vesicle properties, receptor engagement, endocytic routing, intracellular trafficking, and functional readouts, tissue accumulation or cellular uptake alone is insufficient to define effective delivery. This review traces engineered exosome delivery from cellular uptake to therapeutic function, covering engineering strategies, targeting validation, endocytic routing, intracellular fate, and functional readouts. We further discuss the strengths and limitations of commonly used evaluation methods. Across biomedical applications, we emphasize that delivery evidence should be judged according to cargo type, site of action, disease model, and therapeutic mechanism. By linking engineering design, assay selection, and evidence strength, this review supports a more careful interpretation of engineered exosome delivery.

  • Design and application of proton gradient-based pH-responsive nanomaterials in the tumor microenvironment

    by Jianjun Jiang, Limin Jin, Zengkai Zhao, Pengli Gao, Mingmei Li, Xiang Zheng, Fangzhou Li

    The five nanoparticles target the tumor acidic microenvironment through the mechanism of (1) ionizable groups and (2) pH-sensitive chemical bonds.


  • mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy

    by Zengkai Zhao, Mingmei Li, Xiang Zheng, Pengli Gao, Chenlu Huang, Qingyu Yu, Limin Jin, Linhua Zhang, Dunwan Zhu, Fangzhou Li

    Chimeric antigen receptor T cells (CAR-T) immunotherapy has achieved remarkable progress in the treatment of hematological malignancies. However, it encounters challenges including complex manufacturing processes, high cost, and safety issues. Lipid nanoparticle (LNP) technology, as an advanced gene delivery platform, offers significant advancements to CAR-T therapy through its high efficiency, low immunogenicity, and safety. LNP enable in vivo production of CAR-T cells, thereby improving delivery efficiency, reducing the risks of immunogenicity and insertional mutations, simplifying the production process and reducing costs. The scalability and rapid optimization ability of LNP position them as promising candidates for CAR-T cell production. LNP technology is expected to further promote the development of CAR-T immunotherapy and provide safer and more economical treatment options. Therefore, this paper aims to provide a comprehensive and systematic review of the application of LNP in CAR-T therapy. In this review, we initially outline the fundamental design, process, and current challenges of CAR-T therapy. Subsequently, we present the characteristics of LNP, their advantages as a gene delivery vectors, and how they improve the efficacy of CAR-T therapy. Finally, we summarize the current research landscape of LNP applications in CAR-T therapy. This includes enhancing in vitro transfection of T cells, programming T cells in situ, facilitating T-cell activation, alleviating the side effects of CAR-T therapy, and combining CAR-T therapy with other immunotherapies. These advancements will aid in the design of mRNA delivery systems based on LNP, thereby promoting the development of CAR-T therapy.


  • Open Access

    Compensatory effect-based oxidative stress management microneedle for psoriasis treatment

    by Chaoxiong Wu, Xinyu Yang, Kaiyue Yang, Qingyu Yu, Chenlu Huang, Fangzhou Li, Linhua Zhang, Dunwan Zhu

    Reactive oxygen species (ROS) at elevated levels trigger oxidative DNA damage, which is a significant factor in psoriasis exacerbation. However, normal ROS levels are essential for cell signaling, cell growth regulation, differentiation, and immune responses. To address this, we developed ROS control strategies inspired by compensatory effects. DNA nanostructures with the advantage of being more stable than linear nucleic acid molecules in physiological environments were exquisitely fabricated and incorporated into microneedles (MN). These nanostructures regulate ROS levels and facilitate the delivery of IL-17A siRNA to psoriatic lesions. Our findings demonstrate that this transdermal drug delivery system effectively manages ROS levels in the psoriatic microenvironment, inhibiting pyroptosis and abnormal immune activation. Moreover, modulating ROS levels enhances the therapeutic impact of IL-17A siRNA, offering a promising in situ treatment approach for psoriasis.


  • An antigen-capturing and lymph node-targeting nanoparticle for cancer immunotherapy

    by Zhen Zhang, Chen Xu, Ningqiang Gong, Guangchao Qing, Yuxuan Zhang, Yuxuan Shi, Jacob S. Brenner, Fangzhou Li, Fu-Jian Xu, Xing-Jie Liang


  • The development of paliperidone nanocrystals for the treatment of schizophrenia

    by Phattalapol Lhaglham, Luksika Jiramonai, Xing-Jie Liang, Bingchuan Liu, Fangzhou Li

    Schizophrenia is a complex and chronic psychiatric disorder that significantly impacts patients’ quality of life. Ranking 12th among 310 diseases and injuries that result in disability, the number of patients suffering from schizophrenia continues to rise, emphasizing the urgent need for developing effective treatments. Despite the availability of effective antipsychotic drugs, over 80% of patients taking oral antipsychotics experience relapses, primarily caused by non-adherence as the high dosing frequency is required. In this review, we discuss about schizophrenia, its incidence, pathological causes, influencing factors, and the challenges of the current medications. Specifically, we explore nanocrystal technology and its application to paliperidone, making it one of the most successful long-acting antipsychotic drugs introduced to the market. We highlight the clinical advantages of paliperidone nanocrystals, including improved adherence, efficacy, long-term outcomes, patient satisfaction, safety, and cost-effectiveness. Additionally, we address the physicochemical factors influencing the drug’s half-life, which crucially contribute to long-acting medications. Further studies on nanocrystal-based long-acting medications are crucial for enhancing their effectiveness and reliability. The successful development of paliperidone nanocrystals holds great promise as a significant approach for drug development, with potential applications for other chronic disease management.


  • Top Cited Papers
    Open Access

    Microneedles as transdermal drug delivery system for enhancing skin disease treatment

    by Chaoxiong Wu, Qingyu Yu, Chenlu Huang, Fangzhou Li, Linhua Zhang, Dunwan Zhu


  • Faculty Opinions recommendation of In vivo metallophilic self-assembly of a light-activated anticancer drug.

    by Xing-Jie Liang, Fangzhou Li

    This paper entitled, "In vivo metallophilic self-assembly of a light-activated anticancer drug", presents a novel approach to design self-assembling molecular drugs that can form stable supramolecular nanostructures in living mice and act as light-activated anticancer agents. The paper demonstrates that the metallophilic interaction between cyclometalated palladium complexes is strong enough to generate supramolecular nanostructures in vivo, which have a long circulation time and efficient tumour accumulation rate in a skin melanoma tumour model. The paper shows that green light activation leads to efficient tumour destruction due to the type I photodynamic effect generated by the self-assembled palladium complexes, as confirmed by in vitro and in vivo experiments. The paper provides a new strategy to use small molecules as nanodrugs directly in vivo, without the need of dedicated nanocarriers, and introduces metallophilic interactions as a new tool for nanomedicine.